Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.
Calvo. J R JR; Goberna. R R; Guerrero. J M JM
Key Findings
- Thymosin‑alpha‑1 blocks VIP from binding to its receptors on rat immune cells and liver membranes
- It is 160‑ to 6,250‑times less potent than VIP at blocking this binding
- When it does activate the receptors, it only triggers about 25%‑27% of the response that VIP does, acting as a partial agonist
Practical Outcomes
- For most biohackers, thymosin‑alpha‑1 isn’t a powerful tool for boosting VIP‑related pathways like metabolism or immune signaling. Its weak, partial activity means it’s unlikely to provide noticeable benefits on its own, so it doesn’t change typical dosing or protocol recommendations.
Summary
Thymosin‑alpha‑1 can attach to the same receptors that VIP uses, but it does so far weaker and only partially activates them, acting more like a mild, partial copy of VIP rather than a strong substitute.
Abstract
Thymic peptide thymosin alpha 1 (10(-9) to 3 X 10(-7) M) is shown to inhibit the specific binding of [125I]VIP to rat blood mononuclear cells and liver plasma membranes. Thymosin alpha 1 was 160 and 6250 times less potent that VIP at inhibiting [125I]VIP binding to blood mononuclear cells and liver plasma membranes, respectively. Thymosin alpha 1 (10(-10) to 10(-7) M) was weak in stimulating adenylate cyclase activity. Its efficacy is about 25% and 27% that of native VIP in blood mononuclear cells and liver plasma membranes, respectively. Thymosin alpha 1 may behave as a partial VIP agonist in rat.
Study Information
pubmed
1986
10.1007/bf01116540